Cancer Medicine (2019-09-01)

Killer immunoglobulin‐like receptor genotypes and chronic myeloid leukemia outcomes after imatinib cessation for treatment‐free remission

  • Pierre‐Yves Dumas,
  • Emilie Bérard,
  • Claire Bréal,
  • Stéphanie Dulucq,
  • Delphine Réa,
  • Franck Nicolini,
  • Edouard Forcade,
  • Melody Dufossée,
  • Jean‐Max Pasquet,
  • Béatrice Turcq,
  • Audrey Bidet,
  • Noel Milpied,
  • Julie Déchanet‐Merville,
  • Xavier Lafarge,
  • Gabriel Etienne,
  • François‐Xavier Mahon,
  • French Intergroup in Chronic Myeloid Leukemia

Journal volume & issue
Vol. 8, no. 11
pp. 4976 – 4985


Read online

Abstract Background Natural Killer (NK) cells are innate lymphoid cells that can be cytotoxic toward a large panel of solid tumors and hematological malignancies including chronic myeloid leukemia (CML). Such a cytotoxicity depends on various receptors. Killer immunoglobulin‐like receptors (KIR) belong to these receptors and are involved in maturation process, then in the activation abilities of NK cells. Methods: We investigated the prognostic impact of the KIR2DL5B genotype in 240 CML patients included in two clinical trials investigating tyrosine kinase inhibitors (TKI) discontinuation: STIM and STIM2. Results: After adjustment for standard risk factors in CML, we found that the inhibitory receptor KIR2DL5B‐positive genotype was independently related to a delayed second deep molecular remission (HR 0.54, 95% CI [0.32‐0.91], P = 0.02) after TKI rechallenge but not to time to first deep molecular remission or treatment‐free remission rates. Conclusion: These results suggest that KIR2DL5B could carry a role in lymphocyte‐mediated control of leukemic residual disease control in patient with CML relapse.